6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock
Key Takeaways
- Status epilepticus is defined as $\ge 5 \text{ minutes}$ of continuous seizure activity or $\ge 2$ discrete seizures without complete neurological recovery in between.
- Status epilepticus pharmacotherapy escalates from first-line benzodiazepines (Lorazepam \text{ mg}$ IV, Midazolam \text{ mg}$ IM) to second-line non-sedating AEDs (Levetiracetam \text{ mg/kg}$, Fosphenytoin \text{ mg PE/kg}$, Valproate \text{ mg/kg}$).
- Third-line refractory status epilepticus requires continuous anesthetic infusions (Propofol, Ketamine, Pentobarbital) with endotracheal intubation and EEG monitoring.
- Neurogenic shock (loss of sympathetic tone below T6) presents with severe hypotension, profound bradycardia, and warm dry skin; spinal shock is a transient neurological state of motor/reflex loss.
- Neurogenic shock hemodynamics demand maintaining a MAP target of -90 \text{ mmHg}$ for at least 7 days using Norepinephrine or Dopamine to preserve spinal cord perfusion.
6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock
Neurological emergencies involving ongoing seizure activity or acute traumatic spinal cord injury require rapid algorithmic intervention. Uncontrolled status epilepticus causes irreversible neuronal destruction, systemic acidosis, and hyperthermia. High spinal cord injuries disrupt sympathetic output, producing neurogenic shock that severely compromises spinal cord perfusion. Critical Care Paramedics must execute tiered antiepileptic protocols and maintain strict hemodynamic goals to optimize patient survival and functional recovery.
Status Epilepticus: Definition & Operational Timelines
Historically defined as 30 minutes of continuous seizure activity, operational guidelines now establish $T_1$ (5 minutes) as the point at which seizure activity is unlikely to self-terminate and emergency pharmacotherapy must begin.
Operational Definitions
- Status Epilepticus (SE): Continuous seizure activity lasting $\ge 5 \text{ minutes}$, or $\ge 2$ discrete seizure episodes between which the patient does not regain baseline consciousness.
- Refractory Status Epilepticus (RSE): Seizure activity that persists despite adequate doses of a first-line benzodiazepine and a second-line antiepileptic drug (AED).
- Super-Refractory Status Epilepticus (SRSE): Seizure activity that continues or recur 24 hours or more after initiation of continuous anesthetic infusions, or recurs upon weaning anesthetics.
Tiered Pharmacotherapy Escalation for Status Epilepticus
Pharmacological management proceeds in rapid sequential steps to abort seizure activity and prevent excitotoxic brain injury.
| Treatment Phase | Pharmacological Agents | Recommended Dosing & Administration |
|---|---|---|
| Phase 1: Emergent Therapy<br>(0 – 5 to 10 min) | 1st Line: Benzodiazepines<br>• Lorazepam (Ativan)<br>• Midazolam (Versed)<br>• Diazepam (Valium) | • Lorazepam: $4 \text{ mg}$ IV push over 2 min (or $0.1 \text{ mg/kg}$ IV). Preferred IV agent.<br>• Midazolam: $10 \text{ mg}$ IM (if no IV access; or $0.2 \text{ mg/kg}$ IM, max $10 \text{ mg}$).<br>• Diazepam: $10 \text{ mg}$ IV push ($0.2 \text{ mg/kg}$). High lipophilicity results in rapid CNS redistribution. |
| Phase 2: Urgent Control<br>(10 to 20 to 40 min) | 2nd Line: Non-sedating AEDs<br>• Levetiracetam (Keppra)<br>• Fosphenytoin (Cerebyx)<br>• Valproate Sodium (Depacon) | • Levetiracetam: $60 \text{ mg/kg}$ IV (max $4500 \text{ mg}$) over 10–15 min.<br>• Fosphenytoin: $20 \text{ mg PE/kg}$ IV (max $1500 \text{ mg PE}$) at max $150 \text{ mg PE/min}$.<br>• Valproate Sodium: $40 \text{ mg/kg}$ IV (max $3000 \text{ mg}$) over 5–10 min. |
| Phase 3: Refractory SE<br>(> 40 min) | 3rd Line: Anesthetic Infusions<br>• Propofol (Diprivan)<br>• Ketamine<br>• Pentobarbital | • Propofol: Load $1-2 \text{ mg/kg}$ IV, continuous infusion $2-10 \text{ mg/kg/hr}$ ($30-150 \ \mu\text{g/kg/min}$).<br>• Ketamine: Load $1.5-4.5 \text{ mg/kg}$ IV, continuous infusion $1-5 \text{ mg/kg/hr}$.<br>• Pentobarbital: Load $5 \text{ mg/kg}$ IV, infusion $1-5 \text{ mg/kg/hr}$ titrated to burst suppression. |
Critical AED Dosing Considerations
- Fosphenytoin vs. Phenytoin: Fosphenytoin is a water-soluble prodrug measured in Phenytoin Equivalents (PE). Unlike legacy IV Phenytoin, Fosphenytoin does not contain propylene glycol, eliminating the risks of severe hypotension, cardiac dysrhythmias, and purple glove syndrome (tissue necrosis from extravasation).
- Refractory Airway & EEG: Any patient requiring Phase 3 continuous anesthetic infusions must undergo endotracheal intubation, mechanical ventilation, invasive arterial pressure monitoring, and continuous electroencephalography (cEEG) to titrate infusions to electrographic seizure termination or burst suppression.
Acute Spinal Cord Injury (SCI) & Neurogenic vs. Spinal Shock
Traumatic injury to the spinal cord produces two distinct syndromes that are frequently confused: Spinal Shock (a neurological state) and Neurogenic Shock (a hemodynamic state).
Differentiating Spinal Shock and Neurogenic Shock
| Diagnostic Feature | Spinal Shock | Neurogenic Shock |
|---|---|---|
| Underlying Nature | Neurological Recovery Condition | Hemodynamic Distributive Shock |
| Pathophysiology | Sudden transient cessation of all spinal cord electrical activity and reflex arcs below the level of injury. | Loss of sympathetic vascular tone and cardiac sympathetic innervation due to cord lesion at or above T6. |
| Clinical Manifestations | • Flaccid paralysis<br>• Complete loss of deep tendon reflexes<br>• Absence of bulbocavernosus reflex<br>• Loss of somatic sensation | • Severe Hypotension (massive arterial/venous vasodilation)<br>• Profound Bradycardia (unopposed vagal tone)<br>• Warm, Dry Skin & Poikilothermia |
| Duration | Hours to weeks (resolves as spinal reflexes return, progressing to spasticity). | Days to several weeks (requires active vasoactive support). |
Neurogenic Shock Pathophysiology & Presentation
Neurogenic shock occurs following severe cervical or high-thoracic spinal cord injuries (T6 and above). Sympathetic preganglionic neurons originate in the thoracolumbar spinal cord ($T1 - L2$).
Mechanisms of Clinical Triad
- Severe Hypotension: Disruption of descending sympathetic pathways abolishes vascular tone, resulting in profound vasodilation, venous pooling in lower extremities, decreased venous return (preload), and reduced cardiac output.
- Profound Bradycardia: Sympathetic innervation to the heart originates from the $T1 - T4$ cardiac accelerator fibers. Injuries above T4 block cardiac sympathetic stimulation, leaving parasympathetic (vagal) innervation completely unopposed.
- Warm, Dry Skin: Loss of sympathetic control stops peripheral vasoconstriction and sweating below the injury level, causing peripheral blood pooling and skin warmth.
Hemodynamic Management in Neurogenic Shock
Secondary ischemia of the injured spinal cord exacerbates permanent neurological deficits. Maintaining spinal cord blood flow requires strict arterial pressure targets.
Mean Arterial Pressure Target
- MAP Target: Maintain MAP between $85 - 90 \text{ mmHg}$ for at least 7 days following acute spinal cord injury.
- Clinical Purpose: Elevating MAP drives perfusion through damaged, auto-regulated spinal cord microvasculature, preserving marginal motor/sensory pathways.
Fluid Resuscitation & Vasopressor Protocol
- Judicious Fluid Resuscitation: Administer small crystalloid boluses ($500 - 1000 \text{ mL}$ $0.9%$ NS or LR) to correct hypovolemia. Avoid excessive volume resuscitation; excess fluid in the setting of lost vascular tone leads to acute pulmonary edema.
- First-Line Vasopressor — Norepinephrine: Norepinephrine is the primary vasopressor of choice. Its strong $\alpha_1$-adrenergic agonist activity restores systemic vascular resistance (SVR) and arterial vasoconstriction, while its $\beta_1$-agonist activity provides chronotropic and inotropic support to overcome bradycardia.
- Second-Line / Alternative Vasopressor — Dopamine: Dopamine infusion ($5 - 15 \ \mu\text{g/kg/min}$) provides dual $\alpha_1$ and $\beta_1$ stimulation. However, dopamine carries a significantly higher incidence of tachydysrhythmias compared to norepinephrine.
- Phenylephrine Caution: Phenylephrine is a pure $\alpha_1$ agonist. While it increases SVR, it produces reflex bradycardia, which dangerously worsens the profound bradycardia already present in high SCI/neurogenic shock. Phenylephrine should be avoided unless severe tachycardia is present or co-administered with chronotropic agents.
A 28-year-old female patient is experiencing a continuous tonic-clonic seizure that has lasted 7 minutes without interruption. What is the diagnosis, and what is the first-line pharmacological treatment of choice?
Which clinical presentation best distinguishes Neurogenic Shock from Spinal Shock in a patient with a traumatic C5 spinal cord injury?
What is the targeted Mean Arterial Pressure (MAP) goal for acute traumatic spinal cord injury, and which vasoactive agent is preferred to manage neurogenic shock?